![](https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/images/WhitePaper_Default_icon.png)
Transforming Supply Chain Risks Into a Competitive Advantage in the CRO-CDMO Space: The Syngene Story
By Syngene InternationalThe Covid-19 pandemic led to a widespread supply crunch in the life sciences industry and revealed how inadequate existing supply chains are in managing unexpected disruptions of a global scale. The aftermath? Supply chain operations emerging from decades of back-office obscurity to becoming the focal point of board rooms and C-suites today.
In this white paper, we discuss the typical supply chain challenges faced by global CROs and CDMOs. You will also learn how Syngene, a leading CRO-CDMO for small and large molecules, has transformed its supply chain to mitigate these risks and turned them into a competitive advantage.
![](https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/images/WhitePaper_Default_icon.png)